Pfizer's oral GLP-1 drug candidate, danuglipron, has shown promising results that support daily dosing, the company said July 11.
A phase 1 trial tested the experimental obesity medication to evaluate the pharmacokinetics and safety of immediate- and modified-release formulations of danuglipron. The study enrolled healthy adults and assessed four formulations, according to clinicaltrials.gov.
"To date, study results have demonstrated a pharmacokinetic profile supportive of once-daily dosing with a safety profile consistent with prior danuglipron studies including no liver enzyme elevations observed in more than 1,400 study participants," Pfizer said in a news release.
The drugmaker said it will conduct dose optimization studies in the second half of 2024.
The FDA has approved 10 GLP-1 receptor agonist medications, which treat diabetes, weight loss and serious heart conditions. Currently, the only approved oral formulation is Novo Nordisk's Rybelsus (semaglutide), which is indicated for Type 2 diabetes.